Glaukos CFO Alex Thurman sold 10,000 shares worth $1.6 million on July 9, 2026, under a pre-established Rule 10b5-1 trading plan adopted in December 2025. While insider sales can raise concerns, the non-discretionary nature of this transaction and Glaukos' strong growth outlook—including 25% projected revenue growth for 2026 and the promising Epioxa product—suggest the sale does not indicate trouble for the company.

Abbott Laboratories and Glaukos represent two contrasting healthcare investment strategies: Abbott offers stability through diversification, strong profitability, and recent acquisitions like Exact Sciences, while Glaukos provides high-growth potential in specialized ophthalmic treatments with innovative products like iDose and Epioxa. Abbott trades at a lower valuation multiple but faces integration challenges and legal risks, while Glaukos shows rapid 32% revenue growth but remains unprofitable and dependent on a single manufacturing location.

The presbyopia market is projected to grow at a CAGR of 4.9% from 2026-2036, driven by an aging global population and expanding treatment options. The market was valued at USD 11 billion in 2025 across seven major markets, with the US accounting for 50% of the market. Multiple emerging therapies and devices are expected to enter the market, including Phentolamine, MicroLine, GLK-302, and CorVision, alongside already-approved treatments like VUITY, QLOSI, VIZZ, and YUVEZZI.

Nicox plans to fully repay its financial debts by 2026 after successfully licensing NCX 470 globally with Kowa and Ocumension Therapeutics, with New Drug Application submissions expected in the first half of 2026 in the US and later in China.

Nicox anticipates fully repaying its financial debts in 2026 following successful NCX 470 clinical trials and global licensing deals with Kowa and Ocumension Therapeutics, with expected NDA submissions in the U.S. and China in H1 2026.

Glaukos Corporation is focused on developing and commercializing surgical devices and pharmaceutical therapies for glaucoma treatment. The company's iStent product line and global glaucoma and Corneal Health franchises are performing well, despite competition and supply chain challenges. Glaukos is also advancing its pipeline, including iDose TREX, iDose ROCK, and iLution Travoprost.

Boston Scientific Corporation is scheduled to report its Q2 2024 results on July 24. The company is expected to report revenue growth of around 11.7% and adjusted earnings of 58 cents per share. However, the company may face challenges from a challenging supply environment, rising costs, and healthcare staffing shortages.

Truist Securities has raised its price target for Glaukos Corporation shares to $141, citing the company's strong market position and the potential of its iDose product. The firm maintains a Buy rating on the stock.

Top Wall Street analysts have downgraded their ratings on several companies, including Spotify, Visa, Helen of Troy, LegalZoom, and Glaukos, citing various reasons for their bearish outlook.

The global ophthalmic devices market is projected to grow from $6.79 billion in 2023 to $10.22 billion by 2032, driven by the increasing prevalence of eye conditions and technological advancements in diagnosis and treatment.

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Glaukos (GKOS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.